Jiaxin Tian

Oct 24, 2024 | virologyj.biomedcentral.com | Haidi Wu |Jiaxin Tian |Wenbo Shi |Zhi Ye Wang |Yanjun Du |Hongwei Xu | +8 more

In this observational, real-world study, patients who received tixagevimab/cilgavimab from July 9, 2022, to December 30, 2022, in Hainan, China, were included. The inclusion criteria were patients who received tixagevimab/cilgavimab either before the initiation of the study or were prescribed with tixagevimab/cilgavimab thereafter. The patients participating in interventional clinical trials for SARS-CoV-2 prophylactics or treatments were excluded.

Jun 6, 2024 | mdpi.com | Haoran Wang |Jiaxin Tian |Jing Zhao |Ye Zhao

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.